PPARG and non-small cell lung carcinoma: An in vitro study indicated synergy between multiple PPARγ ligands (TRO and PIO) and paclitaxel in A549, H522 non-small-cell lung cancer cells that was dependent upon treatment order, with paclitaxel preceding TRO treatment [33].